🏆 Deal of the Week · CW 15/2024
Reshape raised USD 20 million in a Series A round; the company's valuation was not disclosed. The round was backed by a syndicate that includes Y Combinator, Astanor Ventures, ACME Capital, and 21st.BIO, among others. This deal was recognised as Venionaire DealMatrix's Deal of the Week for KW 15/2024.
Reshape — key deal facts
| Company | Reshape |
| Founded | 2018 |
| Headquarters | Copenhagen, Denmark |
| Amount raised | USD 20M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series A |
| Investors | Y Combinator R7 Partners Per Falholt Nicholas Francis Astanor Ventures ACME Capital 21st.BIO |
| Sectors | Biotechnology |
Who invested in Reshape?
The investor group spans Y Combinator, R7 Partners, Per Falholt, Nicholas Francis, Astanor Ventures, ACME Capital, and 21st.BIO. The mix is notable for combining a leading Silicon Valley accelerator with specialist agri-food and life-science investors, alongside strategic individual backers with deep biotech sector experience. This cross-Atlantic syndicate signals broad confidence in Reshape's platform across both technology and applied biology communities.
What does Reshape do?
Reshape Biotech develops AI and robotics-powered lab automation systems designed for microbiology laboratories. Its core product is a connected platform of intuitive robotic devices paired with an AI-driven cloud operating system that automates visual experiments, data capture, and image analysis. The company was founded in 2018 by Carl-Emil Grøn, Magnus Nyborg Madsen, and Daniel Storgaard, with Carl-Emil Grøn serving as CEO. Reshape is headquartered in Copenhagen, Denmark.
Reshape valuation & multiples
No verified enterprise-value or revenue multiples are available for this transaction, as the post-money valuation was not disclosed. Comparable biotechnology and lab-automation companies are typically benchmarked on EV/Sales and EV/EBITDA ranges that vary materially by development stage and revenue profile. For sector-specific multiples context, visit the Venionaire DealMatrix biotechnology sector multiples pages.
Explore the benchmarks: Series A.
Frequently asked questions
How much did Reshape raise in its Series A?
Reshape raised USD 20 million in its Series A round, recognised as Deal of the Week for KW 15/2024.
What is Reshape's valuation?
Reshape's valuation was not disclosed in connection with this Series A funding round.
Who invested in Reshape?
The Series A investors include Y Combinator, R7 Partners, Per Falholt, Nicholas Francis, Astanor Ventures, ACME Capital, and 21st.BIO.
When was Reshape founded and where is it based?
Reshape Biotech was founded in 2018 and is headquartered in Copenhagen, Denmark.
Source: original announcement — read the full report.